This Clinical Brief was sponsored by Catalyst Pharmaceuticals.
November 5th, 2026Patient Fit Matters Most When Choosing the Right COPD InhalerExperts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.Read more
November 5th, 2026COPD Disease Stability Emerges as a Treatment Target in GOLD 2026Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.Read more
November 5th, 2026CF, Bronchiectasis Antimicrobial Resistance Varies Widely by RegionAntimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.Read more
November 5th, 2026EEOC Reportedly Plans to Narrow Pregnancy Accommodation RulesThe EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.Read more
November 5th, 2026How the GOLD 2026 Guidelines Updated COPD Diagnosis and TreatmentExperts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.Read more
November 5th, 2026Nontargeted ED Screening Offers Best Value in Hepatitis C CareAn economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.Read more
November 5th, 2026Rituximab Maintenance After Frontline BR Linked to Longer MCL SurvivalPooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.Read more
November 5th, 2026Rubber Allergen IPPD Sets Hand Eczema Apart in 6-Year Patch Test StudyAmong 788 patch-tested patients with hand eczema in Shanghai, 82% reacted to at least 1 allergen.Read more